Send to

Choose Destination
Expert Opin Investig Drugs. 2018 Apr;27(4):349-361. doi: 10.1080/13543784.2018.1460356. Epub 2018 Apr 9.

Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy.

Author information

a Department of Neurology, Faculty of Medicine , Mashhad University of Medical Sciences , Mashhad , Iran.
b UC San Diego Department of Neurosciences , Parkinson and Other Movement Disorder Center , La Jolla , CA , USA.


Our understanding of the pathological basis of progressive supranuclear palsy (PSP), as the most common atypical parkinsonian syndrome, has greatly increased in recent years and a number of disease-modifying therapies are under evaluation as a result of these advances. Areas covered: In this review, we discuss disease-modifying therapeutic options which are currently under evaluation or have been evaluated in preclinical or clinical trials based on their targeted pathophysiologic process. The pathophysiologic mechanisms are broadly divided into three main categories: genetic mechanisms, abnormal post-translational modifications of tau protein, and transcellular tau spread. Expert opinion: Once the best therapeutic approaches are identified, it is likely that some combination of interventions will need to be evaluated, but this will take time. It is critical to treat patients at early stages, and development of the Movement Disorder Society PSP diagnostic criteria is an important step in this direction. In addition, development of biological biomarkers such as tau PET and further refinement of tau ligands may help both diagnose early and measure disease progression. In the meantime, a comprehensive, personalized interdisciplinary approach to this disease is absolutely necessary.


Progressive supranuclear palsy; clinical trial; neurodegenerative disorder; tauopathy

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center